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DOI: 10.1016/j.ajpath.2011.05.007CorrectionsIn the article entitled “The Early Growth Response Gene
Egr2 (Alias Krox20) Is a Novel Transcriptional Target of
Transforming Growth Factor- that Is Up-Regulated in Sys-
temic Sclerosis and Mediates Profibrotic Responses” (Vol-
ume 178, pages 2077–2090 of the May 2011 issue of The
American Journal of Pathology), the third author’s name was
listed incorrectly. The correct name is Swati Bhattacharyya.
In the article entitled “AP-1–Mediated M2 Macrophage In-
filtration Underlies IL-1–but Not VEGF-A–Induced Lymph-
and Angiogenesis” (Volume 178, pages 1913–1921 of the
April 2011 issue), HLECswere defined incorrectly. The correct
expansion for HLECs is human lymphatic endothelial cells.
This error occurred in the print article only; the online (HTML
and PDF) versions of this article appear correctly.
In the article entitled “NF-B Inhibition Protects against
Tumor-Induced Cardiac Atrophy in Vivo” (Volume 178,
pages 1059–1068 of the March 2011 issue), the fourth
author’s name was listed incorrectly. The correct name is
Luge Li.
In the article entitled “Bone Marrow-Derived Progenitor
Cells Do Not Contribute to Podocyte Turnover in the Puro-
mycin Aminoglycoside and Renal Ablation Models in Rats”
(Volume 178, pages 494–499 of the February 2011 issue),
the fourth author’s surname was listed incorrectly. The cor-
rect surname name is Agustian. In addition, the author af-
filiation for Jan U. Becker contained errors. The correct
author affiliation is Institute of Pathology, Hannover Medical
School, Hannover, Germany.
In the article entitled “CD4 T Cells Sensitized by Vascular
Smooth Muscle Induce Vasculitis, and Interferon Gamma Is
Critical for the Initiation of Vascular Pathology” (Volume 177,
pages 3215–3223 of the December 2010 issue), panel B was
inadvertently duplicated as panel C in Figure 1.
In the article entitled “-Cell Loss and -Cell Apoptosis
in Human Type 2 Diabetes Are Related to Islet AmyloidDeposition” (Volume 178, pages 2632–2640 of the June
2011 issue), Table 2 contained errors in the definition of
NA. The corrected Table 2, which correctly distinguishes
between parameters with no data (ND) and those with
Figure 1. Vasculitis incidence after transfer of SMC-sensitized lymphocytes is
similar in wt and in B cell-deficient (JhD) mice. A–C. Vasculitis incidence scored
on H&E sections of lung (each diamond depicts a mouse; horizontal bar is
average). Control indicates noninjected mice. A: Adoptive transfer of wt BALB/c
lymphocytes previously sensitized by co-culture (wt mL) with syngeneic SMC to
wt BALB/c recipient mice; n  11, P  0.003 (four experiments). SM are mice
injected with primary smooth muscle cultures (106 cells/mouse). Ly are mice
injected with isolated naïve spleen lymphocytes (5  106 cells/mouse).
B: Transfer of sensitized wt BALB/c lymphocytes to RAG-2-deficient mice; n 
7, P  0.006 (three experiments). C: Transfer of sensitized JhD lymphocytes to
JhD mice; n  12 mice, P  0.00002 (seven experiments). D: H&E staining of
4-m paraffin section of lung 7 days after vasculitis induction in JhD mouse,
showing blood vessels with granulomatous- like inflammation and infiltration of
leukocytes with destruction of vessel wall. L indicates vessel lumen. Scale bar
20 m. Original magnification, 400.data not applicable (NA), is shown below.Table 2. Clinicodemographic Characteristics of Individual Subjects
Age (years)/
Sex
BMI
(kg/m2)
Blood glucose
(mmol/L)
Diabetes duration
(years) Diabetes medication Cause of death
Diabetes group
62/F 30.9 8.53 ND glyburide, insulin pulmonary embolism
78/F 28.3 7.67 2 diet GI hemorrhage
59/M 32.6 7.90 8 insulin cardiac arrest(table continues)
537
538 Corrections
AJP July 2011, Vol. 179, No. 1Table 2. Continued
Age (years)/
Sex
BMI
(kg/m2)
Blood glucose
(mmol/L)
Diabetes duration
(years) Diabetes medication Cause of death
59/M 38.4 7.39 ND insulin leukemia
69/F 21.2 9.50 ND metformin malignancy
81/M 31.4 5.63 ND glyburide, metformin aortic dissection
68/M 27.2 11.42 ND metformin GI hemorrhage
52/M 26.3 9.07 ND none cardiopulmonary failure
61/M 29.7 6.85 14 insulin respiratory failure
71/F 21.3 9.39 10 glyburide coronary artery disease
51/F 41.2 11.11 ND glyburide, insulin malignancy
62/M 35.9 7.46 ND insulin in TPN abdominal hemorrhage
80/F 29.1 8.89 20 acetohexamide,insulin coronary artery disease
61/M 36.3 8.92 12 diet, glipizide sepsis
58/M 34.4 8.29 ND insulin coronary artery disease
71/M 37.5 6.50 27 insulin postoperative complications
74/F 36.0 13.17 ND unknown aspiration pneumonia
37/M 39.7 7.69 3 unknown cardiomyopathy
71/F 21.6 ND 12 glyburide coronary artery disease
70/F 32.8 10.33 ND oral hypoglycemic, unspecified abdominal hemorrhage
69/M 21.3 7.06 10 glyburide coronary artery disease
64/M 22.5 6.47 ND insulin sepsis
40/M 41.2 10.17 ND diet, metformin postoperative complications
28/M 35.8 7.67 1 metformin myelodysplastic syndrome
82/M 25.6 17.06 ND glipizide sepsis
63/F 38.8 10.50 12 insulin malignancy
63/M 26.5 7.11 ND diet malignancy
68/M 25.0 NA ND diet cardiac arrest
82/M 19.0 7.50 2 diet sepsis
Control group
87/F 33.0 5.14 NA NA valvular heart disease
62/M 23.4 5.58 NA NA malignancy
34/M 17.5 5.14 NA NA malignancy
63/F 18.7 5.23 NA NA malignancy
54/F 49.3 5.94 NA NA postoperative complications
82/F 40.9 4.72 NA NA perforated duodenal ulcer
61/F 24.3 5.58 NA NA abdominal hemorrhage
65/M 20.5 6.31 NA NA stroke
21/F 32.2 4.63 NA NA pulmonary embolism
64/M 18.7 6.47 NA NA malignancy
65/F 40.1 4.79 NA NA pulmonary veno-occlusive disease
67/M 24.1 5.12 NA NA malignancy
52/M 24.1 5.26 NA NA malignancy
77/F 26.3 6.08 NA NA sepsis
34/M 28.8 5.44 NA NA malignancy
68/F 18.6 4.86 NA NA malignancy
89/M 17.8 6.07 NA NA malignancy
57/F 19.2 5.87 NA NA malignancy
75/M 22.6 4.94 NA NA pneumonia
66/F 25.7 5.43 NA NA respiratory failure
50/M 28.0 5.50 NA NA cardiac failure
45/M 29.8 4.53 NA NA cardiac arrest
83/F 19.8 5.15 NA NA cardiac arrest
44/F 18.0 5.18 NA NA meningitis
20/F 22.8 4.60 NA NA pulmonary hypertension
42/F 34.0 5.39 NA NA sepsis
88/F 29.2 6.16 NA NA respiratory failure
81/M 27.1 5.56 NA NA respiratory failure
58/M 24.9 5.44 NA NA stroke
19/M 32.7 6.22 NA NA malignancy
46/F 28.1 6.47 NA NA sepsis
78/F 42.4 3.78 NA NA abdominal hemorrhage
75/M 20.9 5.83 NA NA malignancy
72/M 34.9 5.56 NA NA multiple myeloma
82/M 32.5 6.06 NA NA sepsis
94/M 21.9 5.22 NA NA sepsis
68/M 24.0 5.17 NA NA respiratory failure
60/M 15.9 6.94 NA NA respiratory failure
57/M 22.8 5.56 NA NA cardiac arrestF, female; GI, gastrointestinal; M, male; ND, no data; NA, not applicable; TPN, total parenteral nutrition.
